Amgen biyoüretim tesisi, Amgen’in 2027 yılına kadar tüm operasyonlarında karbon nötr olma hedefine ulaşmasına yardımcı olacak şekilde tasarlandı.
Amgen Yönetim Kurulu Başkanı ve İcra Kurulu Başkanı Robert Bradway, Amgen Ohio olarak bilinen yeni tesisin “‘her hastaya, her zaman’ güvenli, güvenilir ilaçlar sunmak üzere en son yenilik ve teknolojiyle tasarlandığını” belirtti. “Amgen’in küresel biyoüretim ağının bir parçası olarak Amgen Ohio, yenilikçi biyomedikal ürünlerimizle dünya çapında ciddi hastalıklara karşı mücadelede bize yardımcı olmada önemli bir rol oynayacak.”
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
THOUSAND OAKS, Calif., Feb. 26, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.
“Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for ‘every patient, every time,'” said Robert A. Bradway, chairman and chief executive officer at Amgen. “As part of Amgen’s global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines.”
The nearly 300,000-square-foot facility will employ 400 full-time staff. It also features open workspaces to foster collaboration and has been designed to meet the highest environmental sustainability standards, in support of Amgen’s commitment to achieve carbon neutrality for all operations by 2027.
